The landscape of medical innovation is often a race against time—not just the time it takes to develop a life-saving tool, but the time it takes for that tool to actually reach the patient’s bedside. In the United States, this transition depends on a complex interplay between the Food and Drug Administration (FDA), which ensures a device is safe and effective, and the Centers for Medicare and Medicaid Services (CMS), which decides if and how the government will pay for it.
A novel proposal from CMS is now threatening to disrupt the financial incentives for some of the most advanced medical technologies. The agency is proposing to repeal a specific payment pathway that has allowed FDA-designated breakthrough devices to qualify for supplementary payments without the traditional requirement of proving they offer a substantial clinical improvement over existing alternatives.
For hospitals, these supplementary payments are often the difference between adopting a new technology and sticking with older, less effective methods. When the cost of a new device exceeds the standard reimbursement rate, hospitals may be reluctant to offer the treatment to avoid financial losses. The proposed rollback could potentially reinstate a higher evidence bar for reimbursement, shifting the financial risk back onto healthcare providers and manufacturers.
The Evolution of Breakthrough Device Payment Flexibilities
To understand why this proposal is significant, one must look at the long-standing rules governing “innovative” devices. Since 2001, Medicare has maintained a system to provide extra payments for devices that meet three specific criteria: they must be new and different from current options, they must offer a demonstrable clinical improvement over existing alternatives, and they must be especially costly to implement.
However, starting in 2021, a “sweeter deal” was established for devices that received a specific “breakthrough designation” from the FDA. Under this flexibility, these devices could qualify for supplementary payments by demonstrating only that they were expensive, effectively bypassing the requirement to prove a substantial clinical improvement over existing options to secure the extra funding.
The FDA grants breakthrough designation to devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions according to the TCET pathway guidelines. By lowering the payment barrier, the 2021 policy aimed to ensure that these high-cost, high-potential innovations didn’t languish in warehouses simply because hospitals couldn’t afford the upfront cost.
A History of Friction: From MCIT to TCET
The current proposal is the latest in a series of ideological shifts regarding how the U.S. Government handles medical breakthroughs. The tension generally pits “rapid access” against “evidence-based payment.”
During the Trump administration, this tension led to the creation of the Medicare Coverage of Innovative Technology (MCIT) pathway. Based on Executive Order 13890, the MCIT rule was designed to provide national Medicare coverage as early as the same day as FDA market authorization for breakthrough devices, with coverage lasting for four years per CMS official fact sheets. This was an attempt to create an “unfettered path” to coverage, allowing manufacturers to opt-in within two years of FDA authorization.
However, this approach was short-lived. In 2021, the Biden administration rescinded the MCIT rule. The decision was driven by concerns that the government was paying for products without sufficient evidence of their long-term effectiveness as reported by EMMA International. This move highlighted the core conflict: even as the FDA might discover a device “safe and effective” for its intended use, CMS requires a different level of evidence to justify the use of public funds for reimbursement.
To address the resulting “coverage gap,” CMS later introduced the Transitional Coverage for Emerging Technologies (TCET) pathway, which became effective on August 12, 2024 according to a Final Notice. The TCET pathway seeks a middle ground, providing “transparent, predictable, and expedited national coverage” for eligible breakthrough devices. Its primary goal is to shorten the typical nine-to-twelve-month gap between FDA clearance and a National Coverage Determination (NCD), which often delays patient access to critical technology.
Why the Current Proposal Matters for Patients and Providers
While TCET focuses on whether a device is covered, the current proposal focuses on how much is paid. If CMS repeals the 2021 payment flexibilities, the impact will be felt across three primary groups:
- Hospitals: Many facilities rely on supplementary payments to offset the high acquisition costs of breakthrough tech. Without these “flexibilities,” hospitals may face a financial deficit when adopting new devices, potentially leading them to decline the use of cutting-edge treatments.
- Manufacturers: The incentive to develop high-cost, specialized devices is tied to the predictability of reimbursement. A return to the stricter “clinical improvement” requirement may slow the pipeline of new devices entering the U.S. Market.
- Patients: For those with life-threatening or debilitating conditions, the “breakthrough” designation represents a glimmer of hope. If the financial burden on hospitals increases, the availability of these devices may shrink, regardless of whether the FDA has authorized them.
The scale of this issue is significant. As of June 2025, more than 1,100 devices have been granted breakthrough designation, though only 160 have been authorized for use according to industry data. A shift in payment policy could affect the trajectory of hundreds of emerging technologies.
Comparative Timeline of Medicare Breakthrough Policies
| Policy/Action | Effective Date/Era | Primary Objective | Outcome/Status |
|---|---|---|---|
| Innovative Device Criteria | Since 2001 | Extra payments for “New, Improved, and Costly” devices | Active baseline standard |
| MCIT Pathway | Trump Admin | Same-day national coverage for 4 years post-FDA authorization | Rescinded in 2021 |
| Payment Flexibilities | Since 2021 | Extra payments based on cost alone for breakthrough devices | Proposed for repeal |
| TCET Pathway | August 12, 2024 | Expedited and predictable national coverage process | Active |
The Broader Policy Implications
This proposal reflects a broader effort by CMS to codify and tighten the definition of what is “reasonable and necessary” for items and services covered under Medicare Part A and Part B per official CMS documentation. By insisting on proven clinical improvement rather than just high cost, the agency is signaling a shift toward value-based care, where payment is tied strictly to improved patient outcomes.
From a public health perspective, the challenge is balancing this fiscal responsibility with the need for innovation. If the bar for “clinical improvement” is set too high too early, the medical community may miss out on technologies that require real-world evidence to prove their worth—evidence that can only be gathered if the devices are actually being used in hospitals.
As an internist and journalist, I have seen how the gap between FDA approval and actual clinical availability can frustrate both physicians and patients. The TCET pathway was a step toward solving the coverage timing problem, but this proposed rollback of payment flexibilities suggests that the financial friction remains a significant hurdle.
The medical community now awaits further guidance on how CMS will define “substantial clinical improvement” in the context of these high-cost devices. Whether the agency will allow for a transitional period of data collection or enforce a strict immediate return to the 2001 standards remains to be seen.
The next official step will be the public comment period and the subsequent final rule issuance from CMS, which will determine if the “sweeter deal” for breakthrough devices officially comes to an end.
Do you believe Medicare should prioritize rapid access to innovation or strict evidence of clinical improvement before providing extra payments? Share your thoughts in the comments below.